John Black


Affiliation: Mayo Clinic
Country: USA


  1. Black J, Walker D, O Kane D, Harmandayan M. Frequency of undetected CYP2D6 hybrid genes in clinical samples: impact on phenotype prediction. Drug Metab Dispos. 2012;40:111-9 pubmed publisher
    ..Four novel genes were identified (CYP2D6*13A1 variants 1 and 2, CYP2D6*13G1, and CYP2D6*13G2), and two novel hybrid tandem structures consisting of CYP2D6*13B + *68×2 + *4-like and CYP2D6*13A1 variant 2 + *1×N were observed. ..
  2. Black J. Narcolepsy: a review of evidence for autoimmune diathesis. Int Rev Psychiatry. 2005;17:461-9 pubmed
    ..Future research must focus on elucidation of immune markers and early ameliorative treatments for narcolepsy. ..
  3. Ji Y, Skierka J, Blommel J, Moore B, VanCuyk D, Bruflat J, et al. Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade. J Mol Diagn. 2016;18:438-445 pubmed publisher
    ..Our study provides evidence in favor of preemptive PGx testing by identifying the risk of a variant being present in the population we studied. ..
  4. Black J, Silber M, Krahn L, Avula R, Walker D, Pankratz V, et al. Studies of humoral immunity to preprohypocretin in human leukocyte antigen DQB1*0602-positive narcoleptic subjects with cataplexy. Biol Psychiatry. 2005;58:504-9 pubmed
    ..The hypothesis that DQB1*0602-positive narcoleptic subjects with cataplexy have IgG reactive to preprohypocretin or its cleavage products was not supported. ..